Academia Services

Benefit from a totally new public-private partnering model

LCGC's protected open-innovation model amplifies translation research ability for the PI using HTS to validate novel target pathways. We provide no-cost access to highly curated collections of drug-filtered, diverse small molecules that have been carefully compiled over decades by the experienced medicinal and computational chemists in industry. Our approach provides new opportunities for out-licensing IP by the TTO and sponsored R&D funding for the PI to advance discoveries from screening made in the home lab or the HTS core. LCGC's own proprietary compound library allows researchers full publication rights. Discover 'druggable' new leads with true licensure value and clear-path development tracks faster by a new way for screening the highest quality structures in pharma's vast chemical collections that are available now.